US FDA slaps Import Alert 66-40 on Dabur's Silvassa drug unit over data integrity lapses
Dabur India disclosed a US FDA Import Alert 66-40 covering certain drug products from part of its Silvassa plant, citing data integrity issues. The company says the hit is immaterial — tied to low-revenue private-label exports — and domestic products are unaffected. Shares slipped 1.32% to ₹422.20.
US FDA issued Import Alert 66-40 on drugs from part of Dabur's Silvassa plant over data integrity lapses. Dabur says impact is immaterial, tied to private-label products with insignificant revenue; domestic products unaffected. Shares fell 1.32%.